MedTrace Logo

Safety of Anticoagulant Therapy After Endoscopic Treatment

NCT04976543 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 86

Last updated 2022-10-12

No results posted yet for this study

Summary

The investigators aimed to verify the efficacy and safety of nadroparin calcium warfarin sequential (NWS) anticoagulation therapy after endoscopic therapy in PVT patients with cirrhosis and AVB.

Conditions

  • Cirrhosis
  • Portal Vein Thrombosis
  • Esophageal and Gastric Varices
  • Anticoagulant-induced Bleeding

Interventions

DRUG

nadroparin calcium-warfarin sequential anticoagulation

The NWS therapy group were given a subcutaneous injection of nadroparin calcium every 12 hours for 1 month and switched to warfarin for 5 months. Warfarin was initiated at least 5 days before nadroparin calcium was stopped. International normalized ratio (INR) was detected every 3-4 days and adjusted carefully by 0.75mg dosage until achieve the target level of 2-3.

Sponsors & Collaborators

  • Liaocheng People's Hospital

    collaborator OTHER

  • Taian City Central Hospital

    collaborator OTHER

  • Qilu Hospital of Shandong University

    lead OTHER

Principal Investigators

  • Yanjing Gao, PhD.MD · Qilu Hospital, Shandong University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-01
Primary Completion
2021-12-31
Completion
2022-06-28

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04976543 on ClinicalTrials.gov